Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
We have tested the hypothesis that the antidiabetic biguanide metformin can be used to manipulate the threshold for stress-induced senescence (SIS), thus accelerating the onset of cancer-protective cellular senescence in response to oncogenic stimuli. Using senescence-prone murine embryonic fibroblasts (MEFs), we assessed whether metformin treatment modified the senescence phenotype that is activated in response to DNA damaging inducers. Metformin significantly enhanced the number of MEFs entering a senescent stage in response to doxorubicin, an anthracycline that induces cell senescence by activating DNA damage signaling pathways (e.g., ATM/ATR) in a reactive oxygen species (ROS)-dependent manner. Using WI-38 and BJ-1 human diploid fibroblasts (HDFs), we explored whether metformin supplementation throughout their entire replicative lifespan may promote the early appearance of the biomarkers of replicative senescence. Chronic metformin significantly reduced HDFs' lifespan by accelerating both the loss of replicative potential and the acquisition of replicative senescence-related biomarkers (e.g., enlarged and flattened cell shapes, loss of arrayed arrangement, accumulation of intracellular and extracellular debris and SA-β-gal-positive staining). Metformin functioned as a bona fide stressful agent, inducing monotonic, dose-dependent, SIS-like responses in BJ-1 HDFs, which are highly resistant to ROS-induced premature senescence. Metformin-induced SIS in BJ-1 fibroblasts was accompanied by the striking activation of several microRNAs belonging to the miR-200s family (miR-200a, miR-141 and miR429) and miR-205, thus mimicking a recently described ability of ROS to chemosensitize cancer cells by specifically upregulating anti-EMT (epithelial-to-mesenchymal transition) miR-200s. Because the unlimited proliferative potential of stem cells results from their metabolic refractoriness to SIS, we finally tested if metformin treatment could circumvent the stress (e.g., ROS)-resistant phenotype of induced pluripotent stem cells (iPSCs). Metformin treatment drastically reduced both the number and the size of iPSC colonies and notably diminished the staining of the pluripotency marker alkaline phosphatase. Our current findings, altogether, reveal for the first time that metformin can efficiently lower the threshold for SIS to generate an "stressed" cell phenotype that becomes pre-sensitized to oncogenic-like stimuli, including DNA damaging, proliferative and/or stemness inducers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“For instance, the convergence of epithelial-to-mesenchymal Transition (EMT)-driven acquisition of stem cell characteristics with enhanced basal autophagy in response to bioenergetic stresses may turn premalignant phenotypes into bona fide tumorinitiating cells that bypass stress- and oncogenic-induced cellular senesce…”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Epidemiological studies have provided relatively consistent results suggesting that people with type 2 diabetes receiving the biguanide derivative metformin demonstrate a lower risk and improved outcomes with most common cancers.(1-11) The negative relationship between metformin usage and cancer incidence and mortalit…”
ResultPark, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Four faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070 · cited 1×
“Originally considered the limit to the proliferative capacity of the cells, the most widely accepted interpretation for the biological function of cellular senescence is that it serves as a mechanism for restricting cancer progression.(29-33) Senescenceinducing stressors such as oxidative damage, DNA damage and/ or on…”
BackgroundThe essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708 · cited 1×
“Studies on human cancer tissues and cancer-prone mice have strongly argued that cellular senescence is a pivotal physiological mechanism in protecting cells against malignant transformation.(23-28) Originally considered the limit to the proliferative capacity of the cells, the most widely accepted interpretation for t…”
BackgroundSenescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · cited 1×
“Studies on human cancer tissues and cancer-prone mice have strongly argued that cellular senescence is a pivotal physiological mechanism in protecting cells against malignant transformation.(23-28) Originally considered the limit to the proliferative capacity of the cells, the most widely accepted interpretation for t…”
BackgroundThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Epidemiological studies have provided relatively consistent results suggesting that people with type 2 diabetes receiving the biguanide derivative metformin demonstrate a lower risk and improved outcomes with most common cancers.(1-11) The negative relationship between metformin usage and cancer incidence and mortalit…”
ResultOxygen sensitivity severely limits the replicative lifespan of murine fibroblasts
Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., & Campisi, J. (2003) · Nature Cell Biology · doi:10.1038/ncb1024 · Cited by 1,116
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028
Cited by
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Reduced Expression of MYC Increases Longevity and Enhances Healthspan
Hofmann, J. W., Zhao, X., De Cecco, M., Peterson, A. L., Pagliaroli, L., Manivannan, J., Hubbard, G. B., Ikeno, Y., Zhang, Y., Feng, B., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.016 · Cited by 293
Metformin‐mediated increase in DICER1 regulates microRNA expression and cellular senescence
Noren Hooten, N., Martin‐Montalvo, A., Dluzen, D. F., Zhang, Y., Bernier, M., Zonderman, A. B., Becker, K. G., Gorospe, M., Cabo, R., & Evans, M. K. (2016) · Aging Cell · doi:10.1111/acel.12469 · Cited by 196
“A previous report found that metformin enhances cellular senescence using different cell model systems and high doses of metformin (1–5 mM) with possible value in cancer therapy (Cufi et al., 2012).”
BackgroundLi, H., & Yang, B. B. (2012) · Oncotarget · doi:10.18632/oncotarget.810 · Cited by 117
Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder
Kshirsagar, V., Thingore, C., & Juvekar, A. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00622-2 · Cited by 66
“Interestingly, there are evidences suggesting that therapies for metabolic disorders like statins and metformin work at the miRNA level (Allen et al. 2012; Cufí et al. 2012).”
Background
Metadata
- Authors
- Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Quirantes, R., Segura-Carretero, A., Micol, V., Joven, J., Bosch-Barrera, J., Del Barco, S., Martin-Castillo, B., Vellon, L., & Menendez, J. A.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2012-03-15
- Volume
- 11
- Issue
- 6
- Pages
- 1235-1246
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2072623038
- Cited by
- 61
- References
- 35
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.